This is a standard preclinical development services engagement with no disclosed financial terms or near-term catalyst. Monitor for future IND filings or clinical trial initiations for EL-22/EL-32, which would represent the next material milestone.
Price Chart
Executive Summary
PMGC Holdings subsidiary NorthStrive Biosciences engaged Charles River Laboratories for analytical characterization work on its EL-22 and EL-32 engineered probiotic programs, supporting IND-enabling development. The contract is a routine preclinical development step with no disclosed financial terms or near-term catalyst.
Key Facts
- NorthStrive Biosciences executed a Statement of Work with Charles River Laboratories (NYSE: CRL) for analytical testing on EL-22 and EL-32.
- Work includes DNA isolation, gene copy-number analysis using nucleic-acid amplification and fluorescent-probe technology.
- Testing will be performed at Charles River's U.S. Biologics Testing sites.
- Program aims to strengthen product characterization and manufacturing consistency as programs advance toward IND-enabling development.
- No financial terms, timeline, or milestone payments disclosed.
Financial Impact
No financial terms disclosed; contract value not stated.
Risk Factors
- No assurance that the planned analytical work will be completed on timeline or generate expected data.
- EL-22 and EL-32 are preclinical; regulatory approval and commercialization are years away and highly uncertain.
- Company has no revenue from this program and may require additional capital to advance development.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3370716 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | Press Release | $3.67 $3.54 | ▼ −3.54% | ▼ −3.34% | $2.71 (−26.27%) |
Sep 18, 2026 5w ago | 8-K | $4.78 $4.42 | ▼ −7.53% | ▼ −9.08% | $2.71 (−43.39%) |
Sep 18, 2026 5w ago | Press Release | $4.78 $4.42 | ▼ −7.53% | ▼ −9.08% | $2.71 (−43.39%) |
Aug 19, 2026 9w ago | Press Release | $0.5603 $0.6100 | ▲ +8.87% | ▲ +9.71% | $2.71 (+382.96%) |
Aug 14, 2026 10w ago | Press Release | $0.9100 $0.8730 | ▼ −4.07% | ▼ −3.59% | $2.71 (+197.36%) |
Jul 29, 2026 12w ago | Press Release | $0.8800 $0.9493 | ▲ +7.88% | ▲ +6.20% | $2.71 (+207.50%) |
Jul 9, 2026 15w ago | 8-K | $1.12 $1.09 | ▼ −2.68% | ▼ −1.91% | $2.71 (+141.61%) |
Jul 1, 2026 16w ago | 8-K | $1.28 $1.18 | ▼ −7.81% | ▼ −7.68% | $2.71 (+111.41%) |
Jun 8, 2026 20w ago | Press Release | $1.59 $1.41 | ▼ −11.32% | ▼ −11.03% | $2.71 (+70.19%) |
Jun 5, 2026 20w ago | 8-K | $1.59 $1.41 | ▼ −11.32% | ▼ −11.03% | $2.71 (+70.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers